	US 12,291,562 B2
	Reagents and assays using modified integrin domains
Vineet Gupta, Chicago, IL (US); and Antonio J. Barbosa, Ave Maria, FL (US)
Assigned to Rush University Medical Center, Chicago, IL (US); and 149 Bio, LLC, Miami, FL (US)
Appl. No. 17/599,625
Filed by Rush University Medical Center, Chicago, IL (US); and 149 Bio, LLC, Miami, FL (US)
PCT Filed Mar. 31, 2020, PCT No. PCT/US2020/025898 § 371(c)(1), (2) Date Sep. 29, 2021, PCT Pub. No. WO2020/205827, PCT Pub. Date Oct. 8, 2020.
Claims priority of provisional application 62/827,461, filed on Apr. 1, 2019.
Prior Publication US 2022/0204585 A1, Jun. 30, 2022
Int. Cl. C07K 14/705 (2006.01); A61K 38/00 (2006.01)

CPC C07K 14/70553 (2013.01) [A61K 38/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/50 (2013.01)]

9 Claims

1. A modified integrin polypeptide comprising at least one amino acid substitution in a metal ion binding site, and at least one conformation specific amino acid substitution selected from the group consisting of F156A, F275S, F275R, F302L and F302W of a wild type integrin polypeptide;

wherein the wild type integrin polypeptide comprises SEQ ID NO: 1; and

wherein the metal ion binding site is selected from the group consisting of metal ion dependent adhesion site (MIDAS), adjacent to MIDAS (ADMIDAS) and ligand-associated metal binding site (LIMBS)/synergistic metal binding site (SyMBS).